GLP-1 Peptide Atlas, by Delfa

UnknownPhase 4

Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes

Effect of the Weekly Administration of Exenatide LAR or Dulaglutide on the Variability of Blood Pressure and Heart Rate of 24 Hours in Patients With Type 2 Diabetes Mellitus Without Pharmacological Treatment.

Lead sponsor

University of Guadalajara

Assets

Dulaglutide / Exenatide

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•Heart rate, change•Systolic BP, change•Diastolic BP, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03444142

Org study IDExenatida LAR Dulaglutida-with

Timeline

Milestones

Study start2017-11-17actual

Study first posted2018-02-23actual

Last update posted2020-03-26actual

Primary completion2021-11-30estimated

Study completion2021-11-30estimated

Assets

Investigational agents

Dulaglutide Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age31 Years

Maximum age60 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients both sexes

•Age between 31 and 60 years

•Diagnosis of diabetes according ADA criteria:

(Fasting blood glucose levels >125 mg/dl or postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose > 200 mg/dl, or glycosylated hemoglobin >6.5%).

• Informed consent signed

Exclusion criteria

•Women with confirmed or suspected pregnancy

•Women under lactation and/or puerperium

•Hypersensibility to ingredients of intervention

•Physical impossibility for apply the drug

•Known pancreatic, renal, hepatic, heart or thyroid diseased

•Hypertension diagnosis

•Previous treatment for glucose

•Body Mass Index ≥39.9 kg/m2

•Triglycerides ≥500 mg/dL

•Total cholesterol ≥300 mg/dL

•Night or rotating shift workers

•Blood Pressure ≥140/90 mmHg

Endpoints (20)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Glycemic / diabetes

MASH / liver

Renal / kidney

Other (unclassified)

Weight & body composition

3 endpoints

Secondary/protocol endpoint

Body Weight

Time frame:Baseline to Week 4

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Body Mass Index

Time frame:Baseline to Week 4

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Waist Circumference

Time frame:Baseline, week 4

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Secondary/protocol endpoint

Fasting glucose levels

Time frame:Baseline to Week 4

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Glycosylated hemoglobin

Time frame:Baseline to Week 4

HbA1c, change

change from baseline, improvement

LOINC 4548-4

MASH / liver

2 endpoints

Secondary/protocol endpoint

Alanine aminotransferase (ALT) levels

Time frame:Baseline to Week 4

ALT, change

change from baseline, improvement

LOINC 1742-6

Secondary/protocol endpoint

Aspartate aminotransferase (AST) levels

Time frame:Baseline to Week 4

AST, change

change from baseline, improvement

LOINC 1920-8

Renal / kidney

1 endpoint

Secondary/protocol endpoint

Creatinine levels

Time frame:Baseline to Week 4

change from baseline, improvement

Cardiometabolic biomarkers

11 endpoints

Primary/protocol endpoint

Heart rate: nighttime, daytime and 24-h

Time frame:Baseline to Week 4

Heart rate, change

change from baseline, improvement

Primary/protocol endpoint

Systolic blood pressure, daytime, night and 24 h

Time frame:Baseline to Week 4

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Primary/protocol endpoint

Diastolic blood pressure, daytime, night and 24 h

Time frame:Baseline to Week 4

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Primary/protocol endpoint

Blood pressure

Time frame:Baseline to Week 4

change from baseline, improvement

Secondary/protocol endpoint

Categories: dipper o non dipper

Time frame:Baseline to Week 4

categorical status, improvement

Secondary/protocol endpoint

Central and peripheral blood pressure

Time frame:Baseline to Week 4

change from baseline, improvement

Secondary/protocol endpoint

Pulse wave velocity

Time frame:Baseline to Week 4

change from baseline, improvement

Secondary/protocol endpoint

Cardio-ankle Vascular Index (CAVI)

Time frame:Baseline to Week 4

change from baseline, improvement

Secondary/protocol endpoint

Total cholesterol

Time frame:Baseline to Week 4

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Triglycerides levels

Time frame:Baseline to Week 4

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

High density lipoprotein (c-HDL) levels

Time frame:Baseline to Week 4

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Uric acid levels

Time frame:Baseline to Week 4

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.